AstraZeneca PLC ADRhedged (AZNH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AstraZeneca PLC ADRhedged (AZNH) trades at $53.74. AstraZeneca PLC ADRhedged invests primarily in American Depositary Receipts (ADRs) of AstraZeneca PLC. The fund operates as a non-diversified entity, focusing its investments in a single company's ADRs. Market cap: $1.60M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for AZNH: AZNH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AZNH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AZNH: 1/1 perspectives are bearish.
How is this calculated? →AstraZeneca PLC ADRhedged (AZNH) Healthcare & Pipeline Overview
AstraZeneca PLC ADRhedged is a non-diversified fund focused on investing in American Depositary Receipts (ADRs) of AstraZeneca PLC, providing investors exposure to a leading global biopharmaceutical company without directly holding its shares. The fund operates within the healthcare sector, specifically targeting the pharmaceutical industry.
What Is the Investment Thesis for AZNH?
The investment thesis for AstraZeneca PLC ADRhedged hinges on the performance and prospects of AstraZeneca PLC. As a non-diversified fund, its value is directly correlated to the success of AstraZeneca PLC's drug pipeline, regulatory approvals, and market penetration. Key value drivers include AstraZeneca's ability to innovate and bring new drugs to market, particularly in oncology, cardiovascular, and respiratory diseases. Growth catalysts include upcoming clinical trial results and potential FDA/EMA approvals for pipeline drugs. Investors should monitor AstraZeneca's financial performance, including revenue growth, R&D spending, and earnings reports. Potential risks include clinical trial failures, regulatory setbacks, and increased competition from other pharmaceutical companies. The fund's non-diversified nature amplifies both the potential gains and losses, making it a higher-risk investment option suitable for investors with a strong conviction in AstraZeneca PLC's future.
Based on FMP financials and quantitative analysis
AZNH Key Highlights
- The fund invests at least 95% of its net assets in AstraZeneca PLC ADRs, indicating a highly concentrated investment strategy.
- As a non-diversified fund, its performance is closely tied to the success of AstraZeneca PLC.
- ADRs provide U.S. investors with a convenient way to invest in a non-U.S. company.
- The fund's value is subject to the risks and opportunities associated with AstraZeneca PLC's operations and the pharmaceutical industry.
- Investors should monitor AstraZeneca's drug pipeline, regulatory approvals, and financial performance to assess the fund's potential.
Who Are AZNH's Competitors?
AZNH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
| IPXL Impax Laboratories, Inc. | $18.30 | +0.55% | 46 | |
| CGEM Cullinan Therapeutics, Inc. | $17.81 | +1.02% | $1.09B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AZNH's Key Strengths?
- Focused investment strategy on AstraZeneca PLC ADRs.
- Provides easy access to a leading global biopharmaceutical company.
- Transparent investment vehicle for tracking AstraZeneca PLC's performance.
What Are AZNH's Weaknesses?
- Non-diversified portfolio, increasing risk.
- Performance is entirely dependent on AstraZeneca PLC's success.
- Subject to currency fluctuations and international market risks.
What Could Drive AZNH Stock Higher?
- Clinical trial results for AstraZeneca PLC's key pipeline drugs.
- Potential FDA/EMA approvals for new therapies developed by AstraZeneca PLC.
- Expansion of AstraZeneca PLC's market share in key therapeutic areas.
- Strategic collaborations and acquisitions by AstraZeneca PLC to enhance its pipeline and market presence.
What Are the Key Risks for AZNH?
- Clinical trial failures for AstraZeneca PLC's pipeline drugs.
- Regulatory setbacks and delays in drug approvals.
- Increased competition from other pharmaceutical companies.
- Economic downturns and geopolitical risks affecting AstraZeneca PLC's operations.
- Currency fluctuations impacting the value of AstraZeneca PLC ADRs.
What Are the Growth Opportunities for AZNH?
- Expansion of AstraZeneca's oncology portfolio: The global oncology market is projected to reach $373.5 billion by 2029, driven by the increasing incidence of cancer and advancements in treatment options. AstraZeneca is actively developing and commercializing new cancer therapies, including targeted therapies and immunotherapies. Successful clinical trials and regulatory approvals in this area could significantly boost AstraZeneca's revenue and, consequently, the value of AstraZeneca PLC ADRhedged. This represents a major growth opportunity for the fund, contingent on AstraZeneca's continued success in oncology research and development.
- Advancements in cardiovascular and metabolic disease treatments: The market for cardiovascular and metabolic disease treatments is substantial, driven by the rising prevalence of conditions like diabetes and heart disease. AstraZeneca has a portfolio of drugs targeting these conditions, and further innovation and market penetration could drive growth. The global cardiovascular drugs market is expected to reach $79.8 billion by 2027. Positive clinical trial outcomes and successful commercialization of new treatments in this area would contribute to AstraZeneca's revenue growth and benefit AstraZeneca PLC ADRhedged.
- Growth in emerging markets: Emerging markets represent a significant growth opportunity for pharmaceutical companies due to increasing healthcare spending and expanding access to medicines. AstraZeneca is actively expanding its presence in these markets, including China, India, and Brazil. Successful market entry and expansion in these regions could drive revenue growth for AstraZeneca and increase the value of AstraZeneca PLC ADRhedged. The emerging markets pharmaceutical sector is projected to experience rapid growth in the coming years, offering substantial potential for AstraZeneca.
- Strategic collaborations and acquisitions: AstraZeneca has a history of engaging in strategic collaborations and acquisitions to expand its pipeline and market presence. These partnerships can provide access to new technologies, drug candidates, and markets. Future collaborations and acquisitions could enhance AstraZeneca's growth prospects and positively impact the value of AstraZeneca PLC ADRhedged. The pharmaceutical industry is characterized by frequent M&A activity, and AstraZeneca's strategic moves in this area could be a significant growth driver.
- Development of novel respiratory therapies: Respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), affect millions of people worldwide. AstraZeneca has a portfolio of respiratory therapies, and further innovation in this area could drive growth. The global respiratory drugs market is expected to reach $44.8 billion by 2027. Successful development and commercialization of new respiratory therapies would contribute to AstraZeneca's revenue growth and benefit AstraZeneca PLC ADRhedged. This represents a key growth opportunity for the fund, contingent on AstraZeneca's continued success in respiratory research and development.
What Opportunities Does AZNH Have?
- Growth in the pharmaceutical industry and AstraZeneca PLC's market share.
- Positive clinical trial results and regulatory approvals for AstraZeneca PLC's pipeline drugs.
- Expansion of AstraZeneca PLC's presence in emerging markets.
What Threats Does AZNH Face?
- Clinical trial failures and regulatory setbacks for AstraZeneca PLC.
- Increased competition in the pharmaceutical industry.
- Economic downturns and geopolitical risks affecting AstraZeneca PLC's operations.
What Are AZNH's Competitive Advantages?
- Access to AstraZeneca PLC ADRs: Provides a specific investment vehicle focused solely on AstraZeneca PLC ADRs.
- Simplicity: Offers a straightforward way for investors to gain exposure to AstraZeneca PLC.
- Cost-effectiveness: Potentially lower transaction costs compared to directly purchasing AstraZeneca PLC shares on international exchanges.
What Does AZNH Do?
AstraZeneca PLC ADRhedged is structured as a fund that concentrates its investments in the American Depositary Receipts (ADRs) of AstraZeneca PLC, a global science-led biopharmaceutical company. The fund's strategy is to allocate at least 95% of its net assets into these ADRs under normal market conditions. Unlike a typical diversified investment fund, AstraZeneca PLC ADRhedged is non-diversified, meaning it focuses its investments on a single entity, AstraZeneca PLC, rather than spreading them across multiple companies or sectors. ADRs are instruments that represent ownership of shares in a non-U.S. company and are held by a U.S. bank or trust. They allow U.S. investors to easily invest in foreign companies without the complexities of cross-border transactions and currency conversions. AstraZeneca PLC, the underlying company, is a major player in the pharmaceutical industry, known for its research, development, and commercialization of prescription medicines. The fund's performance is therefore closely tied to the performance of AstraZeneca PLC. Investors in AstraZeneca PLC ADRhedged are essentially making a concentrated bet on the success and growth of AstraZeneca PLC within the global pharmaceutical market. The fund does not invest directly in AstraZeneca PLC but rather through its ADRs, providing a mechanism for U.S. investors to participate in the company's financial performance.
What Products and Services Does AZNH Offer?
- Invests primarily in American Depositary Receipts (ADRs) of AstraZeneca PLC.
- Provides investors exposure to AstraZeneca PLC without directly holding its shares.
- Operates as a non-diversified fund, concentrating investments in a single company.
- Tracks the performance of AstraZeneca PLC through its ADRs.
- Offers a way for U.S. investors to participate in AstraZeneca PLC's financial performance.
- Aims to replicate the investment results of holding AstraZeneca PLC ADRs.
How Does AZNH Make Money?
- Generates returns based on the performance of AstraZeneca PLC ADRs.
- Passively manages its portfolio to mirror the holdings of AstraZeneca PLC ADRs.
- Charges management fees to cover operational expenses.
- Distributes dividends received from AstraZeneca PLC ADRs to its shareholders.
What Industry Does AZNH Operate In?
AstraZeneca PLC ADRhedged operates within the healthcare sector, specifically targeting the pharmaceutical industry through its investment in AstraZeneca PLC ADRs. The global pharmaceutical market is characterized by high R&D spending, stringent regulatory requirements, and intense competition. Market trends include the increasing demand for innovative therapies, the growing prevalence of chronic diseases, and the rise of personalized medicine. AstraZeneca PLC competes with other major pharmaceutical companies in this landscape. The fund's performance is influenced by these industry dynamics and AstraZeneca PLC's ability to maintain its competitive edge.
Who Are AZNH's Key Customers?
- Retail investors seeking exposure to AstraZeneca PLC.
- Institutional investors looking for a convenient way to invest in AstraZeneca PLC ADRs.
- Investors who believe in the growth potential of AstraZeneca PLC.
- Investors seeking to diversify their portfolio with international exposure.
AZNH Valuation & Market Position
With a $1.60M market cap, AstraZeneca PLC ADRhedged sits in the micro-cap segment of the market.
ROE 0%Key Financial Metrics
Return on equity for AstraZeneca PLC ADRhedged stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. AZNH trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
AZNH Financials
Bull Case vs Bear Case
Bull Case
- Focused investment strategy on AstraZeneca PLC ADRs.
- Provides easy access to a leading global biopharmaceutical company.
- Transparent investment vehicle for tracking AstraZeneca PLC's performance.
- Upcoming: Clinical trial results for AstraZeneca PLC's key pipeline drugs.
Bear Case
- Non-diversified portfolio, increasing risk.
- Performance is entirely dependent on AstraZeneca PLC's success.
- Subject to currency fluctuations and international market risks.
- Potential: Clinical trial failures for AstraZeneca PLC's pipeline drugs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
AZNH Latest News
No recent news available for AZNH.
AZNH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AZNH.
Price Targets
Wall Street price target analysis for AZNH.
AZNH MoonshotScore
What does this score mean?
The MoonshotScore rates AZNH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
AstraZeneca PLC ADRhedged Healthcare Stock: Key Questions Answered
What does AstraZeneca PLC ADRhedged do?
AstraZeneca PLC ADRhedged is a fund that invests primarily in American Depositary Receipts (ADRs) of AstraZeneca PLC, a global biopharmaceutical company. The fund's primary objective is to provide investors with a means to track the performance of AstraZeneca PLC without directly purchasing its shares on international exchanges. By concentrating its investments in AstraZeneca PLC ADRs, the fund offers a focused approach to investing in the pharmaceutical sector, specifically targeting a single company's performance. The fund operates as a non-diversified entity, meaning its performance is heavily reliant on the success and growth of AstraZeneca PLC.
What are the main risks for AZNH?
The main risks for AstraZeneca PLC ADRhedged stem from its non-diversified nature and its dependence on the performance of AstraZeneca PLC. Clinical trial failures for AstraZeneca PLC's pipeline drugs could significantly impact the fund's value. Regulatory setbacks and delays in drug approvals also pose a risk. Increased competition from other pharmaceutical companies could erode AstraZeneca PLC's market share and profitability. Economic downturns and geopolitical risks could affect AstraZeneca PLC's operations and financial performance. Currency fluctuations could impact the value of AstraZeneca PLC ADRs, particularly for U.S. investors. Investors should carefully consider these risks before investing in AZNH.
How does AstraZeneca PLC ADRhedged navigate regulatory approval processes?
As AstraZeneca PLC ADRhedged invests in ADRs of AstraZeneca PLC, its performance is closely tied to AstraZeneca's ability to successfully navigate regulatory approval processes. AstraZeneca PLC must adhere to stringent regulations set by agencies like the FDA in the United States and the EMA in Europe. A strong track record of successful drug approvals is vital for maintaining investor confidence and driving revenue growth. Delays or rejections in the approval process can significantly impact AstraZeneca's stock price and, consequently, the value of AstraZeneca PLC ADRhedged. Investors should monitor AstraZeneca's regulatory filings and announcements to assess potential risks and opportunities.
What is AstraZeneca PLC ADRhedged's drug pipeline status?
The performance of AstraZeneca PLC ADRhedged is significantly influenced by the status of AstraZeneca PLC's drug pipeline. AstraZeneca PLC's pipeline includes drugs in various stages of clinical development, targeting therapeutic areas such as oncology, cardiovascular, and respiratory diseases. Positive clinical trial results and successful progression through regulatory phases are crucial for driving future revenue growth. Investors should monitor key pipeline milestones, including Phase 1, Phase 2, and Phase 3 trial results, as well as regulatory submissions and approvals. Upcoming catalysts include potential FDA/EMA approvals for promising drug candidates, which could positively impact AstraZeneca's stock price and, consequently, the value of AstraZeneca PLC ADRhedged.
What are the key factors to evaluate for AZNH?
Evaluate AZNH on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does AZNH data refresh on this page?
AZNH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AZNH's recent stock price performance?
AstraZeneca PLC ADRhedged (AZNH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused investment strategy on AstraZeneca PLC ADRs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AZNH overvalued or undervalued right now?
Valuing AstraZeneca PLC ADRhedged (AZNH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The fund's performance is highly dependent on the success of AstraZeneca PLC.
- Non-diversified nature increases risk.
- AI analysis pending for more comprehensive insights.